Wedbush Downgrades Sage Therapeutics to Neutral, Announces $22 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Laura Chico has downgraded Sage Therapeutics from Outperform to Neutral and set a price target of $22.
August 07, 2023 | 1:18 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics has been downgraded from Outperform to Neutral by Wedbush, with a new price target of $22.
The downgrade from Outperform to Neutral by Wedbush indicates a less optimistic outlook for Sage Therapeutics. This could potentially lead to a decrease in the stock's price in the short term. The new price target of $22 also suggests a lower valuation for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100